Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC)

Nasopharyngeal carcinoma (NPC) is endemic to Southeast Asia and over 40% of NPC tissues harbor PIK3CA amplifications. This study aims to study the preclinical activity of a novel PI3K inhibitor, BYL719, in 6 NPC cell lines: C666-1, CNE-2, HK1, HK1-EBV, HONE-1 and HONE-1-LMP1. Over 70% of growth inhi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Am J Cancer Res
Autores principales: Wong, Chi Hang, Ma, Brigette Buig Yue, Cheong, Hio Teng, Hui, Connie Wun Chun, Hui, Edwin Pun, Chan, Anthony Tak Cheung
Formato: Artigo
Lenguaje:Inglês
Publicado: e-Century Publishing Corporation 2015
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4473326/
https://ncbi.nlm.nih.gov/pubmed/26101713
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares